Point mutations in the gene encoding copper-zinc superoxide dismutase (SOD1) impart a gain-of-function to this protein that underlies 20-25% of all familial amyotrophic lateral sclerosis (FALS) cases. However, the specific mechanism of mutant SOD1 toxicity has remained elusive. Using the complementary techniques of atomic force microscopy (AFM), electrophysiology, and cell and molecular biology, here we examine the structure and activity of A4VSOD1, a mutant SOD1. AFM of A4VSOD1 reconstituted in lipid membrane shows discrete tetrameric pore-like structure with outer and inner diameters 12.2 and 3.0 nm respectively. Electrophysiological recordings show distinct ionic conductances across bilayer for A4VSOD1 and none for wildtype SOD1. Mouse neuroblastoma cells exposed to A4VSOD1 undergo membrane depolarization and increases in intracellular calcium. These results provide compelling new evidence that a mutant SOD1 is capable of disrupting cellular homeostasis via an unregulated ion channel mechanism. Such a "toxic channel" mechanism presents a new therapeutic direction for ALS research.
Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease characterized by selective loss of motor neurons (MNs) in the brain and spinal cord leading to muscle inactivity and degeneration. At present, no viable treatment exists to alter the course of the disease, with death usually occurring within 1-5 years of the disease onset (Cleveland and Rothstein, 2001) . Approximately 10% of ALS cases are familial (FALS), most typically with an autosomal dominant inheritance pattern (Bruijn et al., 2004) . FALS cases are remarkably similar in clinical manifestations to sporadic ALS (SALS) (Bruijn et al., 2004) . Genetic studies have linked 20-25% of FALS cases to N100 single, missense mutations in the copper-zinc superoxide dismutase type 1 (SOD1) gene located on chromosome 21 (Boillee et al., 2006; Bruijn et al., 2004; Rosen et al., 1993) . These point mutations in the SOD1 locus are reported to induce ALS pathophysiology not by "loss of function" as supported by the three lines of evidence: i) some of the mutant forms of SOD1 that induce FALS have full dismutase activity; ii) an SOD −/− mouse does not develop ALS; and iii) mice that carry mutant SOD1 as a transgene develop ALS, despite a normal endogenous dismutase activity (reviewed in (Boillee et al., 2006) ). These findings suggests an alternate competing notion that mutated SOD1 acquires a toxic "gain of function" to induce the disease. Despite the identification of mutant SOD1 as a cause of ALS for almost 20 years, the specific toxic function gained by mutant SOD1 that causes the selective loss of MNs has remained elusive. High molecular weight aggregates of mutant SOD1 have been detected in cell extracts from FALS patients, FALS transgenic mice and cultured cells (Bruening et al., 1999; Bruijn et al., 1998; Johnston et al., 2000) and they have been linked to ALS disease progression, however, the structural and functional details of these aggregates are not fully characterized. Significantly, mutant SOD1 forms misfolded aggregates and kills MNs because of its acquired toxicity rather than its diminished dismutase activity (Ghadge et al., 2006; Gurney et al., 1994; Reaume et al., 1996) . Several findings, including a reduction in mutual repulsive charge and increase in hydrophobicity, have been reported for the genetic mutants of SOD1 and are likely to contribute to the misfolding and aggregation of mutant SOD1 peptides (Sandelin et al., 2007; Tiwari et al., 2005) . Recent studies also suggest that SALS may also be caused by a similar SOD1 neurotoxicity related to misfolding 
Contents lists available at SciVerse ScienceDirect
Neurobiology of Disease j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y n b d i
